ArticleFrontiers in cellular and infection microbiology2023
Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method.
Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Effect of vitamin D supplementation on COVID-19 outcomes: an umbrella review of systematic reviews.Frontiers in nutrition · 2025Pooled it
- Exploring the interplay between posttraumatic stress disorder, gut microbiota, and inflammatory biomarkers: a comprehensive meta-analysis.Frontiers in immunology · 2024Pooled it
- Shotgun Metagenomics Reveals Gut Microbiome Remodeling with Altered Taxonomic Composition and Functional Potential in Diabetic Dogs.Animals : an open access journal from MDPI · 2026Article
- Crosstalk between gut microbiota and RNA N6-methyladenosine modification in diabetic retinopathy.Frontiers in cell and developmental biology · 2026Review
- The Role of Probiotics and Their Postbiotic Metabolites in Post-COVID-19 Syndrome.Molecules (Basel, Switzerland) · 2025Review
- Reactivation of Latent Tuberculosis Following COVID-19 and Epstein-Barr Virus Coinfection: A Case Report.Pathogens (Basel, Switzerland) · 2025Article
- Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease.Frontiers in microbiology · 2025Review
- Metformin as a disease-modifying therapy in osteoarthritis: bridging metabolism and joint health.Frontiers in pharmacology · 2025Article
- mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy.Frontiers in bioengineering and biotechnology · 2025Review
- Recent advances in the management of knee osteoarthritis: a narrative review.Frontiers in medicine · 2025Review
- Microbial Dynamics in COVID-19: Unraveling the Impact of Human Microbiome on Disease Susceptibility and Therapeutic Strategies.Current microbiology · 2024Review
- Review
- The interplay of gut microbiota, obesity, and depression: insights and interventions.Cellular and molecular life sciences : CMLS · 2024Review
- HbA1c and leukocyte mtDNA levels as major factors associated with post-COVID-19 syndrome in type 2 diabetes patients.Scientific reports · 2024Article
- Exploring the Efficacy of Alpha-Lipoic Acid in Comorbid Osteoarthritis and Type 2 Diabetes Mellitus.Nutrients · 2024Article
- Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions.Biomedicines · 2024Review
- Metformin Alters mRNA Expression ofViruses · 2024Article
- Article
- Nutrition at the Intersection between Gut Microbiota Eubiosis and Effective Management of Type 2 Diabetes.Nutrients · 2024Review
- Predictive analysis of osteoarthritis and chronic pancreatitis comorbidity: complications and risk factors.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global pandemic of coronavirus disease 2019 (COVID-19) continues to affect people around the world, with one of the most frequent comorbidities being Type 2 Diabetes (T2D). Studies have suggested a link between disbalances in gut microbiota and these diseases, as well as with COVID-19, potentially due to inflammatory dysfunction. This study aims to analyze the changes in gut microbiota in COVID-19 patients with T2D using a culture-based method. Methods: The stool samples were taken from 128 patients with confirmed COVID-19. Changes in the composition of gut microbiota were analyzed by culture-based method. The study used chi-squared and t-test to find significant differences in gut bacteria between samples and non-parametric correlation analysis to examine relationship between gut bacteria abundance, C-reactive protein (CRP) levels and length of stay (LoS) in COVID-19 patients without T2D. Results: The gut microbiota of T2D patients with COVID-19 showed increased Conclusion: In conclusion, this study provides important insights into the gut microbiota composition of SARS-CoV-2-infected individuals with T2D and its potential impact on the course of the disease. The findings suggest that certain gut microbiota genera may be associated with increased CRP levels and longer hospital stays. The significance of this study lies in the fact that it highlights the potential role of gut microbiota in the progression of COVID-19 in patients with T2D, and may inform future research and treatment strategies for this patient population. The future impact of this study could include the development of targeted interventions to modulate gut microbiota in order to improve outcomes for COVID-19 patients with T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.